Dietary Magnesium
Magnesium is the fourth most abundant mineral in the human body (~24 g total) and the second most abundant intracellular cation (after K⁺). Critically, serum magnesium — the routine clinical measure — reflects only ~1% of total body magnesium, making deficiency assessment challenging and deficiency chronically underdiagnosed. Absorbed via TRPM6 (intestinal/renal) and TRPM7 (ubiquitous); homeostasis is dominated by renal handling (loop of Henle + distal convoluted tubule). The Mg-ATP chelate complex is the true substrate for virtually all ATP-utilizing enzymes — hexokinase, Na⁺/K⁺-ATPase, DNA polymerase, RNA polymerase, ATP synthase all require Mg-ATP, not free ATP⁴⁻. Mg²⁺ also provides the voltage-dependent block of the NMDA receptor ion channel at resting membrane potential — the coincidence-detection mechanism underlying synaptic plasticity. IV MgSO₄ is first-line treatment for eclampsia (Magpie trial: 58% ↓ seizures) and torsades de pointes.
Overview
Magnesium (Mg, atomic number 12) is the fourth most abundant mineral in the human body and the second most abundant intracellular cation after potassium. Total body magnesium is approximately 24 g (1,000 mmol), distributed as ~60% in bone (bound to hydroxyapatite crystal lattice as long-term reserve), ~39% intracellular (predominantly skeletal muscle; ~95% complexed as Mg-ATP, with <5% as free Mg²⁺ at ~0.5–1.0 mmol/L), and ~1% extracellular (serum 0.75–1.05 mmol/L). The critical clinical implication: serum magnesium reflects only ~1% of total body magnesium — normomagnesaemia can coexist with substantial intracellular or bone depletion, making deficiency assessment with standard serum values highly insensitive.
Dietary magnesium comes primarily from green vegetables (magnesium is the central metal atom of chlorophyll), nuts and seeds, legumes, whole grains, and dark chocolate. Approximately 50% of American adults consume below the Estimated Average Requirement (EAR) for magnesium (Rosanoff et al., 2012), with median intake of ~250–270 mg/day — well below the RDA of 310–420 mg/day. This widespread subclinical deficiency is linked epidemiologically to type 2 diabetes, hypertension, migraine, cardiovascular disease, and depression, though establishing causation vs. confounding remains challenging.
Magnesium is simultaneously a mundane dietary mineral and a critical pharmacological agent. Oral magnesium supplements vary enormously in bioavailability — magnesium oxide (~4% absorbable) is the cheapest and worst-absorbed form and should be avoided for repletion; magnesium glycinate, citrate, and malate provide markedly superior bioavailability. Intravenous magnesium sulfate (MgSO₄) is one of a small number of truly life-saving therapeutic agents: first-line for eclampsia, torsades de pointes, and severe asthma exacerbations.
Mechanism of Action
Intestinal Absorption: TRPM6/TRPM7
Dietary Mg2+ (jejunum / ileum)
|
| TRPM6 (SLC-independent Mg2+ channel; apical brush-border of enterocytes)
| Upregulated by: estrogen, EGF, insulin, hypomagnesemia
| Downregulated by: anti-EGFR therapy (cetuximab) -> clinical hypomagnesemia
| TRPM7 (ubiquitous; forms heteromers with TRPM6; has alpha-kinase domain)
| Feedback-inhibited by intracellular Mg2+
| Paracellular (claudin-7/12 tight-junction channels; high-dose/supplemental)
v
Enterocyte -> TRPM6-mediated basolateral exit -> portal vein
|
v
─── KIDNEY (dominant homeostatic site) ────────────────────
~65% reabsorbed in thick ascending limb (TAL):
Paracellular via paracellin-1 (claudin-16/19); lumen-positive voltage (NKCC2)
FUROSEMIDE BLOCKS NKCC2 -> major renal Mg2+ wasting
~15% reabsorbed in distal convoluted tubule (DCT):
Transcellular via TRPM6; fine-tuning
Calcineurin inhibitors (tacrolimus/cyclosporin) -> downregulate DCT TRPM6
~3-5% excreted (adjusts to match intake)
─── THE Mg-ATP COMPLEX ─────────────────────────────────────
Nearly all ATP-utilizing enzymes require Mg2+ as Mg-ATP:
Mg2+ coordinates beta- and gamma-phosphates of ATP4-
-> stabilises ATP for nucleophilic phosphoryl-transfer
Examples: Hexokinase, PFK1, pyruvate kinase, Na+/K+-ATPase,
SERCA, DNA pol, RNA pol II, ATP synthase, aminoacyl-tRNA synthetases
─── NMDA RECEPTOR BLOCK ─────────────────────────────────────
At resting Vm (~-70 mV):
Extracellular Mg2+ occupies NMDAR channel pore -> blocks Ca2+/Na+ flux
Even when glutamate + glycine are bound, Mg2+ block prevents current
On depolarisation (AMPA-R activation):
Positive Vm repels Mg2+ from pore -> Ca2+ influx through NMDAR
-> Hebbian coincidence detection -> LTP / synaptic plasticity
Mg2+ deficiency: -> lower threshold NMDAR activation -> hyperexcitability
- TRPM6-mediated intestinal absorption: Selective Mg²⁺ channel on enterocyte apical membrane; upregulated by estrogen and EGF; downregulated by anti-EGFR biologics (cetuximab causes clinically significant hypomagnesaemia in ~50% of treated patients).
- Renal fine-tuning (dominant homeostasis): ~65% reabsorbed paracellularly in TAL (NKCC2-driven lumen-positive voltage; furosemide-sensitive); ~15% transcellularly in DCT via TRPM6.
- Mg-ATP cofactor: Virtually all phosphotransferase reactions require Mg²⁺-ATP chelate as the true substrate; free ATP⁴⁻ is a poor substrate for kinases and ATPases. Deficiency → impaired glycolysis, Na⁺/K⁺-ATPase function, and DNA replication.
- NMDA receptor voltage-dependent block: Extracellular Mg²⁺ physically blocks the NMDAR ion channel at resting potential; coincidence-detection mechanism for Hebbian plasticity and LTP. Deficiency → lower seizure threshold, migraine susceptibility.
- Cardiovascular: eNOS, SERCA, Kir2.x: Mg²⁺ activates eNOS → ↑NO → vasodilation; supports SERCA Ca²⁺ re-uptake; physiological Ca²⁺ channel blocker in vascular smooth muscle and cardiomyocytes; blocks inward rectifier K⁺ channels (Kir2.x) → influences QTc interval.
Pleiotropic Roles
Migraine Pathophysiology
Low brain Mg²⁺ (documented by ³¹P-MRS in migraineurs) lowers threshold for cortical spreading depression (CSD) — the electrophysiological correlate of migraine aura — via increased NMDAR sensitivity. Mg supplementation (400–600 mg/day) reduces migraine frequency ~40–50% (AAN Grade B).
Cardiac Electrophysiology
Mg²⁺ physiological calcium channel blockade in cardiomyocytes shortens QTc and reduces early after-depolarisations (EADs). IV MgSO₄ terminates torsades de pointes even when serum Mg is normal — the therapeutic mechanism is direct membrane stabilisation, not repletion.
Insulin Signalling
Insulin receptor tyrosine kinase is an Mg-ATP-dependent enzyme. Mg deficiency → impaired insulin receptor signalling → ↑insulin resistance. Prospective cohorts: highest vs. lowest Mg intake → ~15–20% ↓ T2DM incidence; RCTs show ↓HOMA-IR with supplementation in deficient individuals.
Glutathione Synthesis
Glutathione synthetase (GSH-S) requires Mg-ATP as substrate. Mg deficiency → ↓GSH synthesis → ↑oxidative stress — creating a mechanistic link between Mg inadequacy and oxidative-stress-associated chronic diseases.
Dietary Sources & RDA
| Source | Serving | Magnesium Content | % RDA (men <31: 400 mg) |
|---|---|---|---|
| Pumpkin seeds (roasted) | 1 oz (28 g) | 156 mg | 39% |
| Chia seeds | 1 oz | 111 mg | 28% |
| Spinach (boiled) | ½ cup | 78 mg | 20% |
| Almonds | 1 oz (28 g) | 77 mg | 19% |
| Dark chocolate (70–85%) | 1 oz (28 g) | 64 mg | 16% |
| Black beans (cooked) | ½ cup | 60 mg | 15% |
| Quinoa (cooked) | ½ cup | 59 mg | 15% |
| Avocado | 1 medium (150 g) | 58 mg | 15% |
RDA: Men 19–30: 400 mg/day; Men ≥31: 420 mg/day; Women 19–30: 310 mg/day; Women ≥31: 320 mg/day; Pregnant: 350–360 mg/day. No established Tolerable Upper Intake Level for dietary magnesium from food (excess excreted via urine); supplemental UL 350 mg/day elemental (to prevent osmotic diarrhoea).
Clinical Evidence
| Trial / Evidence | Design | Key Result | GRADE |
|---|---|---|---|
| Magpie Trial (2002) Eclampsia prevention |
RCT; n=10,141 women with pre-eclampsia; IV MgSO₄ vs. placebo | MgSO₄ → 58% ↓ eclamptic seizures (RR 0.42; 95% CI 0.29–0.60). Trend towards ↓ maternal mortality. First-line standard of care globally for severe pre-eclampsia/eclampsia seizure prevention. | High (Grade A) |
| Torsades de Pointes (consensus / case series) |
Clinical consensus; multiple case series | IV MgSO₄ (1–2 g over 1–2 min) is first-line treatment for torsades de pointes, effective even when serum Mg is normal. Mechanism: QTc shortening via Ca²⁺ channel blockade, ↓EADs. | High (consensus/standard care) |
| Migraine Prevention (multiple RCTs; AAN review) |
Multiple RCTs (400–600 mg/day Mg oxide or citrate); AAN/AHS evidence review | Mg supplementation → ~40–50% ↓ migraine frequency vs. placebo. AAN/AHS rates as “probably effective” (Grade B). Effect strongest in migraineurs with aura (documented low brain Mg²⁺ by ³¹P-MRS). | Moderate (Grade B) |
| Type 2 Diabetes (prospective cohorts + RCTs) |
Prospective cohorts; RCTs of Mg supplementation in T2DM/pre-DM | Highest vs. lowest Mg intake: ~15–20% ↓ T2DM incidence in prospective cohorts. RCTs: ↓HOMA-IR and ↓fasting glucose in Mg-deficient subjects. Confounding cannot be fully excluded in observational data. | Moderate (observational + RCT) |
Evidence principle: IV MgSO₄ has the strongest evidence in acute hospital medicine — Grade A for eclampsia (Magpie trial) and consensus first-line for torsades de pointes. For oral supplementation, migraine prevention is the best-supported indication (AAN Grade B). The widespread subclinical deficiency (50% of US adults) and magnesium’s role in >300 enzymatic reactions support optimising dietary intake even absent overt deficiency symptoms. Critical assessment limitation: serum Mg is insensitive — a normal serum level does not exclude cellular magnesium depletion.
Deficiency & Excess
| Status | Signs & Symptoms | Lab Marker | Threshold |
|---|---|---|---|
| Subclinical deficiency (most common; normal serum Mg) |
Fatigue, muscle cramps, impaired exercise performance, insomnia, anxiety, mild hypertension, ↑migraine frequency; links to T2DM and CVD in epidemiological data | Serum Mg (insensitive); RBC Mg (more sensitive); 24-hr urinary Mg (<24 mg/day suggests deficiency); Mg loading test (retention >50% after IV load suggests cellular deficiency) | Serum Mg may be normal despite 30–50% body depletion |
| Clinical hypomagnesaemia | Muscle weakness, tremor, tetany (hypocalcaemia secondary to impaired PTH secretion), ventricular arrhythmias (torsades), seizures, personality changes; often co-exists with hypokalaemia (Mg required for K⁺ reabsorption) | Serum Mg <0.75 mmol/L; ECG (QTc prolongation, flattened T waves) | Serum Mg <0.75 mmol/L; severe <0.5 mmol/L |
| Adequate | Normal neuromuscular function, cardiac rhythm, blood pressure, insulin sensitivity | Serum Mg 0.75–1.05 mmol/L | RDA 310–420 mg/day |
| Hypermagnesaemia (almost always iatrogenic) |
Mild: nausea, flushing, ↓BP. Moderate: loss of deep tendon reflexes (Mg ~4–5 mmol/L). Severe: respiratory paralysis, cardiac arrest (Mg >6–7 mmol/L). Almost exclusively from IV MgSO₄ therapy or renal failure + Mg supplementation. | Serum Mg; clinical monitoring of DTRs and respiratory rate during IV therapy | Toxicity threshold ~2.5 mmol/L (serum); DTR loss ~4 mmol/L; respiratory arrest ~6 mmol/L. Calcium gluconate is the antidote (IV Ca²⁺ antagonises Mg²⁺ effects). |
Connections
References
- de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. Physiol Rev. 2015;95(1):1-46. doi:10.1152/physrev.00012.2014 · PubMed 25540137
- Rosanoff A, Weaver CM, Rude RK. Suboptimal magnesium status in the United States: are the health consequences underestimated? Nutr Rev. 2012;70(3):153-64. doi:10.1111/j.1753-4887.2011.00465.x · PubMed 22364157
- Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877-90. doi:10.1016/S0140-6736(02)08778-0
- Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16(4):257-63. doi:10.1046/j.1468-2982.1996.1604257.x
- Berg JM, Tymoczko JL, Stryer L. Biochemistry. 9th ed. W.H. Freeman; 2019. Chapter on metal ions in enzyme catalysis and Mg-ATP.
- Hall JE, Hall ME. Guyton and Hall Textbook of Medical Physiology. 14th ed. Elsevier; 2021. Chapters on mineral homeostasis and renal tubular transport.